Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Purwin

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|January 15, 2020
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanomaManoela Tiago, Claudia Capparelli, Dan A Erkes, et al.
Molecular Cancer Research : MCR|April 15, 2022
Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal MelanomaUsman Baqai, Timothy J Purwin, Nelisa Bechtel, et al.
Molecular Cancer Research : MCR|December 13, 2024
Metabolic Inhibition Induces Pyroptosis in Uveal MelanomaScott D Varney, Dan A Erkes, Glenn L Mersky, et al.
Cell Reports|December 8, 2021
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effectsSheera R Rosenbaum, Manoela Tiago, Signe Caksa, et al.
Pigment Cell & Melanoma Research|May 8, 2019
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated mannerDan A Erkes, Conroy O Field, Claudia Capparelli, et al.
Oncogene|January 29, 2021
Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitorsAnna Han, Timothy J Purwin, Nelisa Bechtel, et al.
Oncogene|November 19, 2020
BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitorsAnna Han, Timothy J Purwin, Nelisa Bechtel, et al.
Cancer Research|August 18, 2018
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS MelanomaClaudia Capparelli, Timothy J Purwin, Shea A Heilman, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Molecular Cancer Therapeutics|July 5, 2019
<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in MelanomaIleine M Sanchez, Timothy J Purwin, Inna Chervoneva, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|January 15, 2020
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanomaManoela Tiago, Claudia Capparelli, Dan A Erkes, et al.
Molecular Cancer Research : MCR|April 15, 2022
Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal MelanomaUsman Baqai, Timothy J Purwin, Nelisa Bechtel, et al.
Molecular Cancer Research : MCR|December 13, 2024
Metabolic Inhibition Induces Pyroptosis in Uveal MelanomaScott D Varney, Dan A Erkes, Glenn L Mersky, et al.
Cell Reports|December 8, 2021
SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effectsSheera R Rosenbaum, Manoela Tiago, Signe Caksa, et al.
Pigment Cell & Melanoma Research|May 8, 2019
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated mannerDan A Erkes, Conroy O Field, Claudia Capparelli, et al.
Oncogene|January 29, 2021
Correction to: BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitorsAnna Han, Timothy J Purwin, Nelisa Bechtel, et al.
Oncogene|November 19, 2020
BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitorsAnna Han, Timothy J Purwin, Nelisa Bechtel, et al.
Cancer Research|August 18, 2018
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS MelanomaClaudia Capparelli, Timothy J Purwin, Shea A Heilman, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Molecular Cancer Therapeutics|July 5, 2019
<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in MelanomaIleine M Sanchez, Timothy J Purwin, Inna Chervoneva, et al.
Pageof 5